What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|June 15||Weekly Gain||My Watchlist|
KIT digital was last week's biggest winner. The online video asset manager revealed that it's in talks with several potential buyers of the company. Then again, it remains to be seen how many are still interested in KIT now that news of a potential acquisition has moved the stock 50% higher.
The Food and Drug Administration isn't likely to make a decision on Arena Pharmaceuticals' obesity drug lorcaserin until next week, but investors seem to like its chances of receiving regulatory approval.
Rambus landed some favorable analyst coverage when Sidoti & Company set a $10 price target along with its buy rating. That's not too shabby for a stock that began the week below the $5 mark.
Dendreon soared after Summer Street initiated coverage of the biotech with a buy rating. Summer Street isn't exactly a household name among analyst firms, but the ambitious $18 price target certainly got heads turning.
Enterprise portal applications specialist BroadVision moved sharply higher on Friday after investors saw the kind of premium that social collaborator Yammer received in a buyout.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, there's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
The Motley Fool owns shares of Dendreon. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.
More from The Motley Fool
Predicting Dendreon's Next CEO's Future
Its time to play Fool in the blank
Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon
Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.
Why Wall Street Hates Dendreon Corp.
Stocks with heavy short interest might signal that something is terribly wrong with a company. Dendreon Corp. sports one of the highest short interests among health-care stocks. Why are short-sellers so bearish on this small-cap biotech?